EDA KAYA, SİNEM AKSOY, NAZLİCAN ORUC, CAGLA TASDEMİR, BEYZA IREM CENGİZ, ÇAĞLAYAN KEKLİKKIRAN, YUSUF YİLMAZ
Hepatology Forum - 2025;6(3):111-115
Background and Aim: Resmetirom received conditional Food and Drug Administration (FDA) approval in 2024 for metabolic dysfunction-associated steatotic liver disease (MASLD) based on its promising liver-targeted therapy. Clinical trials required a histological diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) with F2-F3 fibrosis, excluding cirrhosis, while real-world prescribing relies on non-invasive tests (NITs). This study evaluates their efficacy in identifying the target population within a biopsy-proven Turkish MASLD cohort.
